LDL‐C and hs‐CRP Jointly Modify the Effect of Lp(a) on 5‐Year Death in Patients With Percutaneous Coronary Intervention
Clinical Cardiology · 2024
DOI: 10.1002/clc.70025 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Jiawen Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Cardiovascular Disease, Department of Cardiology, National Clinical Research Center for Cardiovascular Diseases, Fu Wai Hospi…. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Lipoprotein(a), C-Reactive Protein, Coronary Artery Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The research was funded by the National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences (grant number….
Abstract (Originalsprache)
Background
Recent studies have suggested that adverse events associated with lipoprotein(a) [Lp(a)] might be modified by low‐density lipoprotein cholesterol (LDL‐C) or high‐sensitivity C‐reactive protein (hs‐CRP) levels, but whether LDL‐C and hs‐CRP jointly mediate the outcome of Lp(a) remains unknown in patients with coronary artery disease. Methods and Results A prospective study was conducted, enrolling consecutive 10 724 patients with percutaneous coronary intervention (PCI) in 2013. The endpoint event was all‐cause death. A total of 10 000 patients with complete baseline data were finally included. During a median follow‐up of 5.1 years, Lp(a) ≥ 30 mg/dL was an independent risk factor of all‐cause death in the overall population, LDL‐C ≥ 70 mg/dL, and hs‐CRP ≥ 2 mg/L population, respectively. According to concurrent LDL‐C (70 mg/dL) and hs‐CRP (2 mg/L) levels, further analysis revealed that when LDL‐C < 70 mg/dL regardless of hs‐CRP levels, Lp(a) ≥ 30 mg/dL was not an independent predictor of all‐cause death. However, when LDL‐C ≥ 70 mg/dL, Lp(a) ≥ 30 mg/dL was independently associated with a higher risk of all‐cause death in hs‐CRP ≥ 2 mg/L (HR: 1.488, 95% CI: 1.059‒2.092), but not in hs‐CRP < 2 mg/L (HR: 1.303, 95% CI: 0.914‒1.856).
Conclusion
Among PCI patients, Lp(a)‐associated outcome was jointly affected by LDL‐C and hs‐CRP. As long as LDL‐C is well controlled, the adverse effects of increased Lp(a) on cardiovascular risk seem to be weakened, and only when LDL‐C and hs‐CRP increase at the same time, elevated Lp(a) is associated with poorer long‐term outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Cardiovascular Disease, Department of Cardiology, National Clinical Research Center for Cardiovascular Diseases, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of M…
Förderung
- The research was funded by the National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences (grant number…
Zitieren
APA
Li, J., Yan, K., Zhu, P., Tang, X., Yang, Y., Gao, R., Yuan, J., & Zhao, X. (2024). LDL‐C and hs‐CRP Jointly Modify the Effect of Lp(a) on 5‐Year Death in Patients With Percutaneous Coronary Intervention. Clinical Cardiology. https://doi.org/10.1002/clc.70025
Vancouver
Li J, Yan K, Zhu P, Tang X, Yang Y, Gao R, et al. LDL‐C and hs‐CRP Jointly Modify the Effect of Lp(a) on 5‐Year Death in Patients With Percutaneous Coronary Intervention. Clinical Cardiology. 2024. doi:10.1002/clc.70025
BibTeX
@article{Li2024,
author = {Li, Jiawen and Yan, Kailun and Zhu, Pei and Tang, Xiaofang and Yang, Yuejin and Gao, Runlin and Yuan, Jinqing and Zhao, Xueyan},
title = {LDL‐C and hs‐CRP Jointly Modify the Effect of Lp(a) on 5‐Year Death in Patients With Percutaneous Coronary Intervention},
journal = {Clinical Cardiology},
year = {2024},
doi = {10.1002/clc.70025}
}
EUVIMED